Baxter/$BAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Ticker
$BAX
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
38,000
ISIN
US0718131099
Website
Baxter Metrics
BasicAdvanced
$15B
-
-$1.10
0.61
$0.80
2.29%
Price and volume
Market cap
$15B
Beta
0.61
52-week high
$39.71
52-week low
$26.25
Average daily volume
3.8M
Dividend rate
$0.80
Financial strength
Current ratio
2.021
Quick ratio
1.147
Long term debt to equity
136.759
Total debt to equity
191.472
Interest coverage (TTM)
2.54%
Profitability
EBITDA (TTM)
1,887.25
Gross margin (TTM)
39.27%
Net profit margin (TTM)
-5.20%
Operating margin (TTM)
9.12%
Effective tax rate (TTM)
20.71%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
2.50%
Return on equity (TTM)
-3.51%
Valuation
Price to revenue (TTM)
1.409
Price to book
2.18
Price to tangible book (TTM)
-4.29
Price to free cash flow (TTM)
79.459
Free cash flow yield (TTM)
1.26%
Free cash flow per share (TTM)
37.38%
Dividend yield (TTM)
2.69%
Forward dividend yield
2.29%
Growth
Revenue change (TTM)
15.36%
Earnings per share change (TTM)
-121.01%
3-year revenue growth (CAGR)
-7.01%
10-year revenue growth (CAGR)
1.51%
3-year earnings per share growth (CAGR)
-19.33%
10-year earnings per share growth (CAGR)
-12.84%
3-year dividend per share growth (CAGR)
-6.35%
10-year dividend per share growth (CAGR)
-7.83%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Bulls say / Bears say
Baxter's forward P/E ratio of 11.22 suggests anticipated earnings improvements, indicating market confidence in the company's strategic initiatives to enhance its bottom line. (Director's Talk Interviews)
The company's substantial free cash flow of approximately $1.7 billion showcases robust operational cash generation, providing financial flexibility for future growth initiatives. (Director's Talk Interviews)
Analysts exhibit cautious optimism towards Baxter, with 6 buy ratings, 11 hold ratings, and a single sell rating, and an average target price of $38.34, suggesting a notable upside potential of 25.22% from current levels. (Director's Talk Interviews)
Baxter's dividend payout ratio stands at an alarming 464%, surpassing sustainable levels and raising questions about the viability of future dividend payments without substantial earnings improvements. (Director's Talk Interviews)
The company's return on equity (ROE) is reported at -3.51%, pointing to challenges in generating returns from shareholder equity. (Director's Talk Interviews)
Baxter's net income is currently negative, with an EPS of -0.52, indicating profitability challenges that may impact investor confidence. (Director's Talk Interviews)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Baxter News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Baxter stock?
Baxter (BAX) has a market cap of $15B as of July 12, 2025.
What is the P/E ratio for Baxter stock?
The price to earnings (P/E) ratio for Baxter (BAX) stock is 0 as of July 12, 2025.
Does Baxter stock pay dividends?
Yes, the Baxter (BAX) stock pays dividends to shareholders. As of July 12, 2025, the dividend rate is $0.8 and the yield is 2.29%. Baxter has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Baxter dividend payment date?
The next Baxter (BAX) dividend payment date is unconfirmed.
What is the beta indicator for Baxter?
Baxter (BAX) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.